Company Analysis

eXoZymes Inc. (EXOZ)

Nasdaq: EXOZ · Biological Products, (No Diagnostic Substances) · Monrovia, CA · filing with the SEC since 2024
Grade5.3
◀ Past 5.7● Present 4.5▶ Future 5.6
6 est.

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

2 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to eXoZymes Inc.’s names, not what it holds today.

Patents granted
2
2 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and none in 2023
Applications published
5
2 of them in 2025
Names they are printed under
1
a former name
By yearGrantedApplications published
'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name1 counted
Invizyne Technologies, Inc. a former name
US, as the owner printed on each patent
2 granted
5 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 10, 202412,084,689Prenyltransferase variants with increased thermostabilityBiotechnologyInvizyne Technologies, Inc.
Dec 6, 202211,518,983Prenyltransferase variants with increased thermostabilityBiotechnologyInvizyne Technologies, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jun 12, 20252025/0188050RECOMBINANT POLYPEPTIDES WITH BERBERINE BRIDGE ENZYME ACTIVITY USEFUL FOR THE BIOSYNTHESIS OF CANNABINOIDSBiotechnologyInvizyne Technologies, Inc.
Feb 6, 20252025/0043319BIOSYNTHESIS OF CYCLOLAVANDULYL DERIVATIVES OF AROMATIC COMPOUNDSOrganic fine chemistryInvizyne Technologies, Inc.
Mar 7, 20242024/0076699BIOSYNTHESIS OF SUBSTITUTED COMPOUNDS AND CANNABINOIDSBiotechnologyInvizyne Technologies, Inc.
Mar 30, 20232023/0098978PRENYLTRANSFERASE VARIANTS WITH INCREASED THERMOSTABILITYBiotechnologyInvizyne Technologies, Inc. · patent 12,084,689 granted from it
Dec 22, 20222022/0403349PRENYLTRANSFERASE VARIANTS WITH INCREASED THERMOSTABILITYBiotechnologyInvizyne Technologies, Inc. · patent 11,518,983 granted from it
What it applied for, 2024 to 2025: Biotechnology 2 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton EXOZ · research, not advice